[go: up one dir, main page]

CL2010001175A1 - Vaccine composition comprising a viral protein antigen 2 (vp-2) of the virus causing infectious bursitis disease (ibdv). - Google Patents

Vaccine composition comprising a viral protein antigen 2 (vp-2) of the virus causing infectious bursitis disease (ibdv).

Info

Publication number
CL2010001175A1
CL2010001175A1 CL2010001175A CL2010001175A CL2010001175A1 CL 2010001175 A1 CL2010001175 A1 CL 2010001175A1 CL 2010001175 A CL2010001175 A CL 2010001175A CL 2010001175 A CL2010001175 A CL 2010001175A CL 2010001175 A1 CL2010001175 A1 CL 2010001175A1
Authority
CL
Chile
Prior art keywords
ibdv
vaccine composition
viral protein
protein antigen
virus causing
Prior art date
Application number
CL2010001175A
Other languages
Spanish (es)
Inventor
Mahesh Kumar
Jeffrey Harold Rodenberg
Kalen Cookson
Original Assignee
Zoetis W Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34994418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2010001175(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis W Llc filed Critical Zoetis W Llc
Publication of CL2010001175A1 publication Critical patent/CL2010001175A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición de vacuna que comprende un antígeno de proteinaviral 2 (Vp-2) del virus causante de la enfermedad de la bursitis infecciosa (Ibdv).Vaccine composition comprising a proteinaviral 2 (Vp-2) antigen of the virus causing infectious bursitis disease (Ibdv).

CL2010001175A 2004-03-12 2010-10-26 Vaccine composition comprising a viral protein antigen 2 (vp-2) of the virus causing infectious bursitis disease (ibdv). CL2010001175A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55298904P 2004-03-12 2004-03-12

Publications (1)

Publication Number Publication Date
CL2010001175A1 true CL2010001175A1 (en) 2011-04-08

Family

ID=34994418

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010001175A CL2010001175A1 (en) 2004-03-12 2010-10-26 Vaccine composition comprising a viral protein antigen 2 (vp-2) of the virus causing infectious bursitis disease (ibdv).

Country Status (17)

Country Link
US (3) US7338661B2 (en)
EP (2) EP1722814B1 (en)
JP (1) JP4845874B2 (en)
KR (1) KR101172921B1 (en)
CN (1) CN1930284B (en)
AR (1) AR048429A1 (en)
AU (1) AU2005222604B2 (en)
BR (1) BRPI0508660A (en)
CA (1) CA2557844C (en)
CL (1) CL2010001175A1 (en)
CO (1) CO5721019A2 (en)
ES (1) ES2608599T3 (en)
IL (1) IL177903A (en)
MX (1) MXPA06010377A (en)
NZ (1) NZ549687A (en)
WO (1) WO2005089795A2 (en)
ZA (1) ZA200607609B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ549687A (en) * 2004-03-12 2008-08-29 Wyeth Corp Infectious bursal disease virus antigenic isolates and vaccines
KR101511712B1 (en) * 2013-04-03 2015-04-13 주식회사 카브 Novel infectious bursal disease virus IBD K7 and infectious bursal disease vaccine using the same
NZ788649A (en) * 2016-06-02 2025-05-30 Zoetis Services Llc Vaccine against infectious bronchitis
CN108126191B (en) * 2016-12-01 2021-04-06 普莱柯生物工程股份有限公司 Vaccine composition and preparation method and application thereof
CN108653724B (en) * 2017-04-01 2020-11-27 普莱柯生物工程股份有限公司 Vaccine composition for preventing egg drop syndrome of poultry, and preparation method and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530831A (en) * 1982-11-02 1985-07-23 Akzo N.V. Infectious Bursal Disease vaccine
US6471962B1 (en) 1987-06-14 2002-10-29 The University Of Maryland Monoclonal antibodies for infectious bursal disease, vaccines and assays for use therewith
US5192539A (en) 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US5614409A (en) * 1989-05-30 1997-03-25 Commonwealth Scientific And Industrial Research Organisation Production of IBDV VP2 in highly immunogenic form
US5919461A (en) 1989-10-18 1999-07-06 Akzo Nobel N.V. Nonpathogenic infectious bursal disease virus and vaccine
NZ235474A (en) 1989-10-18 1992-12-23 Univ Maryland Virus capable of inducing infectious bursal disease; assay and vaccine
US5595912A (en) * 1990-05-04 1997-01-21 University Of Maryland College Park Specific DNA and RNA sequences associated with US IBDV variants, vector carrying DNA sequences, host carrying cloned vector, deduced amino acid sequences, vaccine and method of vaccination
WO1991016925A1 (en) * 1990-05-04 1991-11-14 University Of Maryland At College Park Specific dna sequences related to an ibdv protein including vectors, hosts and vaccines
IL103939A (en) 1992-12-01 1996-09-12 Abic Ltd Vaccine for the prevention of infectious bursal disease in poultry comprising live attenuated IBD virus
US5605792A (en) * 1993-11-04 1997-02-25 The Ohio State University Research Foundation Infectious bursal disease virus VP2 fusion protein expressed by baculovirus, use as diagnostic
US5788970A (en) * 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
CN1202378A (en) * 1997-06-02 1998-12-23 财团法人化学及血清疗法研究所 Process for preparing infectious bursal disease virus and avian reovirus using cell lines
US6159472A (en) * 1998-11-16 2000-12-12 Akzo Nobel N.V. Intradermal Avian immunization with inactivated vaccines
US6764684B2 (en) * 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
EP1483287A1 (en) * 2002-03-01 2004-12-08 Akzo Nobel N.V. An infectious bursal disease virus variant
MXPA05010113A (en) * 2003-03-24 2005-11-23 Akzo Nobel Nv Infectious bursal disease virus mutants and vaccines.
NZ549687A (en) * 2004-03-12 2008-08-29 Wyeth Corp Infectious bursal disease virus antigenic isolates and vaccines

Also Published As

Publication number Publication date
WO2005089795A3 (en) 2006-02-23
JP2007528900A (en) 2007-10-18
US20050266019A1 (en) 2005-12-01
EP2272949A2 (en) 2011-01-12
ES2608599T3 (en) 2017-04-12
NZ549687A (en) 2008-08-29
CN1930284A (en) 2007-03-14
US20080193480A1 (en) 2008-08-14
EP2272949A3 (en) 2011-01-19
CA2557844A1 (en) 2005-09-29
CA2557844C (en) 2016-06-21
US8323658B2 (en) 2012-12-04
ZA200607609B (en) 2008-07-30
AU2005222604A1 (en) 2005-09-29
WO2005089795A2 (en) 2005-09-29
AR048429A1 (en) 2006-04-26
BRPI0508660A (en) 2007-08-14
AU2005222604B2 (en) 2011-08-11
CN1930284B (en) 2010-06-23
MXPA06010377A (en) 2007-02-14
EP1722814B1 (en) 2016-11-09
KR20060130726A (en) 2006-12-19
JP4845874B2 (en) 2011-12-28
IL177903A0 (en) 2006-12-31
IL177903A (en) 2015-04-30
US7338661B2 (en) 2008-03-04
CO5721019A2 (en) 2007-01-31
EP1722814A2 (en) 2006-11-22
KR101172921B1 (en) 2012-08-13
US20110123560A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
EA200900784A1 (en) VACCINES INCLUDING ANTIGENS FROM FOUR STRAINS OF THE INFLUENZA VIRUS
ECSP045300A (en) VIRAL ANTIGENS
EA200802170A1 (en) LYOPHILIZED COMPOSITION OF THERAPEUTIC PEPTIDE ANTIBODY
CY1118492T1 (en) NOROVIRUS VACCINE PHARMACEUTICAL FORMS
CY1118372T1 (en) NEW METHOD AND COMPOSITIONS
MXPA05009580A (en) Influenza virus vaccine.
CY1111552T1 (en) USE OF HPV16 AND HPV18 AS A VACCINE AGAINST ONE OR MORE OVOGENIC HPV TYPE 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
CY2013036I2 (en) ANTI-NAISSERIA VACCINE COMPOSITIONS CONTAINING A COMBINATION OF ANTIGENS
DE60121136D1 (en) Proteasome-INFLUENZA VIRUS VACCINE COMPOSITION
BRPI0418317A (en) neutralization epitope-based growth enhancement vaccine
DK1526175T4 (en) Coronavirus, nucleic acid, protein and methods for generating vaccine, drugs and diagnostics
DK1881845T3 (en) Nipah virus vaccines
DE602004020189D1 (en) ADJUVANT INFLUENZA VACCINE
CL2010001175A1 (en) Vaccine composition comprising a viral protein antigen 2 (vp-2) of the virus causing infectious bursitis disease (ibdv).
ATE489967T1 (en) HCV VACCINE
HUP0302265A2 (en) A recombinant newcastle disease virus nucleoprotein mutant as a marker vaccine
AR052392A1 (en) MUTANTS OF PROTEIN N OF THE VIRUS SYNDROME REPRODUCTIVE AND RESPIRATORY OF THE PORCINES
DK1375670T3 (en) Recombinant measles viruses expressing epitopes of RNA virus antigens and use of the recombinant viruses to prepare vaccine compositions
EP1623015A4 (en) HA1 EXPRESSING DNA VACCINE FROM EQUIN 2 INFLUENZA VIRUS
ATE555794T1 (en) REMEDIES FOR HEPATITIS
ATE370745T1 (en) IMPROVED POLYSACCHARIDE AND GLYCOCONJUGATE VACCINES
EP1856250A4 (en) NEW VACCINES LIVING VIRUSES
NO20040995L (en) Subunit vaccine for infectious pancreatic necrosis virus
ES2417019T8 (en) Characterization procedure of infectious bursitis disease virus
EP1399481A4 (en) RECOMBINANT ANTIBODIES TO INFECTIOUS BURSAL DISEASE VIRUS (IBDV)